Our study delineated the CYP1B1-USP5-HIF2α signalling cascade as a critical resistance mechanism and thus reveals a targetable vulnerability in treatment-refractory ccRCC. This evidence concerns the gene USP5 and nonpapillary renal cell carcinoma.